AI English summary of an SEC filing — figures as filed
IDEXX Laboratories IDXXIDEXX said revenue for Q3 2026 was $1,214 million, up 10% on both a reported and organic basis, and diluted earnings per share (EPS) were $4.01, up 18% as reported and 22% on a comparable basis.
Key points
AI summaryIDEXX said revenue for Q3 2026 was $1,214 million, up 10% on both a reported and organic basis, and diluted earnings per share (EPS) were $4.01, up 18% as reported and 22% on a comparable basis.
The company said CAG Diagnostics recurring revenue for Q3 grew 11% on both an as-reported and organic basis, with International up 13% as reported and U.S. up 10%. IDEXX VetLab consumables revenue rose 14% as reported.
The company set its full-year 2026 revenue guidance at $4,741 million to $4,767 million, versus prior guidance of $4,700 million to $4,745 million. It set its EPS outlook at $14.96 to $15.16, compared with prior guidance of $14.69 to $14.94.
The company reported that operating cash flow for the 9 months ended September 30, 2026 was $1,063,127 thousand, and free cash flow was $977,567 thousand. It used $810,014 thousand for share repurchases over the same period.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
IDEXX Q3 revenue $1,214 million, diluted EPS $4.01
IDEXX said revenue for Q3 2026 was $1,214 million, up 10% on both a reported and organic basis, and diluted earnings per share (EPS) were $4.01, up 18% as reported and 22% on a comparable basis.
Source · Based on the filing body and exhibits
CAG Diagnostics Recurring Revenue Up 11% in Q3
The company said CAG Diagnostics recurring revenue for Q3 grew 11% on both an as-reported and organic basis, with International up 13% as reported and U.S. up 10%. IDEXX VetLab consumables revenue rose 14% as reported.
Source · Based on the filing body and exhibits
Full-Year 2026 Revenue and EPS Outlook Issued
The company set its full-year 2026 revenue guidance at $4,741 million to $4,767 million, versus prior guidance of $4,700 million to $4,745 million. It set its EPS outlook at $14.96 to $15.16, compared with prior guidance of $14.69 to $14.94.
Source · Based on the filing body and exhibits
9-Month Operating Cash Flow of $1,063,127 thousand
The company reported that operating cash flow for the 9 months ended September 30, 2026 was $1,063,127 thousand, and free cash flow was $977,567 thousand. It used $810,014 thousand for share repurchases over the same period.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
You can verify the report’s figures and statements in the original filing on SEC EDGAR.